Cao M, Wang R, Cheng X, Yu H, Tong Q, Yao Y
Onco Targets Ther. 2025; 18:319-324.
PMID: 40066235
PMC: 11892363.
DOI: 10.2147/OTT.S484293.
Ma L, Luan Y, Lu L
Cancer Med. 2025; 14(5):e70622.
PMID: 40062730
PMC: 11891933.
DOI: 10.1002/cam4.70622.
Weddle C, Blancard M, Uche N, Pongpamorn P, Cejas R, Burridge P
NPJ Precis Oncol. 2025; 9(1):53.
PMID: 40000798
PMC: 11862011.
DOI: 10.1038/s41698-025-00837-5.
Huang L, Han L, Liang S, Han G
Cell Biol Toxicol. 2025; 41(1):52.
PMID: 40000487
PMC: 11861033.
DOI: 10.1007/s10565-024-09980-4.
Xie C, Chan L, Pang Y, Shang Y, Wang W, Zhao L
Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39998626
DOI: 10.1007/s00210-025-03927-0.
EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI.
Chaudhary N, Choudhary B, Shivashankar A, Manna S, Ved K, Shaikh S
Cancer Cell Int. 2025; 25(1):55.
PMID: 39972345
PMC: 11841279.
DOI: 10.1186/s12935-025-03691-4.
Tumour-wide RNA splicing aberrations generate actionable public neoantigens.
Kwok D, Stevers N, Etxeberria I, Nejo T, Colton Cove M, Chen L
Nature. 2025; 639(8054):463-473.
PMID: 39972144
PMC: 11903331.
DOI: 10.1038/s41586-024-08552-0.
Single-cell copy number calling and event history reconstruction.
Kuipers J, Tuncel M, Ferreira P, Jahn K, Beerenwinkel N
Bioinformatics. 2025; 41(3).
PMID: 39946094
PMC: 11897432.
DOI: 10.1093/bioinformatics/btaf072.
Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling.
Regner M, Garcia-Recio S, Thennavan A, Wisniewska K, Mendez-Giraldez R, Felsheim B
Cell Genom. 2025; 5(2):100765.
PMID: 39914387
PMC: 11872555.
DOI: 10.1016/j.xgen.2025.100765.
CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance.
Man K, Darweesh O, Hong J, Thompson A, OConnor C, Bonaldo C
Oncogene. 2025; .
PMID: 39890967
DOI: 10.1038/s41388-025-03284-5.
Cancer phylogenetic inference using copy number alterations detected from DNA sequencing data.
Lu B
Cancer Pathog Ther. 2025; 3(1):16-29.
PMID: 39872371
PMC: 11764021.
DOI: 10.1016/j.cpt.2024.04.003.
Intercellular signaling stabilizes single-cell level phenotypic transitions and accelerates the reestablishment of equilibrium of heterogeneous cancer cell populations.
Lopez D, Tyson D, Hong T
bioRxiv. 2025; .
PMID: 39803530
PMC: 11722408.
DOI: 10.1101/2025.01.03.631250.
Advances and applications in single-cell and spatial genomics.
Wang J, Ye F, Chai H, Jiang Y, Wang T, Ran X
Sci China Life Sci. 2025; .
PMID: 39792333
DOI: 10.1007/s11427-024-2770-x.
Single-cell transcriptomes of dissecting the intra-tumoral heterogeneity of breast cancer microenvironment.
Chen P, Liang K, Mao X, Wu Q, Chen Z, Jin Y
J Cancer Res Clin Oncol. 2024; 151(1):17.
PMID: 39724260
PMC: 11671554.
DOI: 10.1007/s00432-024-06015-7.
Genetic and microenvironmental evolution of colorectal liver metastases under chemotherapy.
Shi M, Yang Y, Huang N, Zeng D, Mo Z, Wang J
Cell Rep Med. 2024; 5(12):101838.
PMID: 39631402
PMC: 11722126.
DOI: 10.1016/j.xcrm.2024.101838.
A global sensitivity analysis of a mechanistic model of neoadjuvant chemotherapy for triple negative breast cancer constrained by in vitro and in vivo imaging data.
Lorenzo G, Jarrett A, Meyer C, DiCarlo J, Virostko J, Quaranta V
Eng Comput. 2024; 40(3):1469-1499.
PMID: 39620056
PMC: 11607094.
DOI: 10.1007/s00366-023-01873-0.
TLN1: an oncogene associated with tumorigenesis and progression.
Li S, Chen A, Gui J, Zhou H, Zhu L, Mi Y
Discov Oncol. 2024; 15(1):716.
PMID: 39589610
PMC: 11599537.
DOI: 10.1007/s12672-024-01593-x.
PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State.
Killarney S, Mesa G, Washart R, Mayro B, Dillon K, Wardell S
Cancer Discov. 2024; 15(3):595-615.
PMID: 39560431
PMC: 11875962.
DOI: 10.1158/2159-8290.CD-24-0928.
Research progress and the prospect of using single-cell sequencing technology to explore the characteristics of the tumor microenvironment.
Zhang W, Zhang X, Teng F, Yang Q, Wang J, Sun B
Genes Dis. 2024; 12(1):101239.
PMID: 39552788
PMC: 11566696.
DOI: 10.1016/j.gendis.2024.101239.
Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies.
Iweala E, Amuji D, Oluwajembola A, Ugbogu E
Curr Res Pharmacol Drug Discov. 2024; 7:100204.
PMID: 39524211
PMC: 11543557.
DOI: 10.1016/j.crphar.2024.100204.